SCA
MRNA icon

Snowden Capital Advisors’s Moderna MRNA Stock Holding History

Snowden Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$364K Sell
5,196
-7,526
-59% -$389K 0.01% 990
2026
Q1 		$646K Buy
12,722
+155
+1% +$7.23K 0.02% 686
2025
Q4 		$371K Sell
12,567
-9,398
-43% -$255K 0.01% 958
2025
Q3 		$567K Sell
21,965
-90,599
-80% -$2.53M 0.02% 718
2025
Q2 		$3.11M Buy
+112,564
New +$2.96M 0.09% 224
2024
Q3 		– Sell
-2,897
Closed -$344K – 1249
2024
Q2 		$344K Buy
2,897
+345
+14% +$43.7K 0.01% 921
2024
Q1 		$272K Buy
+2,552
New +$257K 0.01% 993
2023
Q3 		– Sell
-3,210
Closed -$390K – 1141
2023
Q2 		$390K Buy
3,210
+153
+5% +$20.4K 0.01% 849
2023
Q1 		$469K Buy
3,057
+433
+17% +$71.4K 0.02% 759
2022
Q4 		$471K Sell
2,624
-621
-19% -$102K 0.02% 726
2022
Q3 		$383K Sell
3,245
-316
-9% -$47.9K 0.02% 774
2022
Q2 		$508K Sell
3,561
-1,579
-31% -$226K 0.02% 625
2022
Q1 		$885K Buy
5,140
+2,518
+96% +$424K 0.04% 473
2021
Q4 		$665K Sell
2,622
-804
-23% -$235K 0.03% 402
2021
Q3 		$1.32M Buy
3,426
+6
+0.2% +$2.21K 0.07% 317
2021
Q2 		$804K Buy
3,420
+50
+1% +$8.94K 0.04% 422
2021
Q1 		$441K Buy
3,370
+105
+3% +$15.2K 0.03% 524
2020
Q4 		$341K Sell
3,265
-748
-19% -$75.7K 0.02% 505
2020
Q3 		$284K Buy
+4,013
New +$280K 0.02% 477

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Snowden Capital Advisors's MRNA Position: Q2 2026 in Review

Snowden Capital Advisors reduced its Moderna (MRNA) stake by 59% in Q2 2026, selling an estimated $389K and leaving 5,196 shares worth $364K. The position accounts for 0.01% of the portfolio, ranked #990.

Snowden Capital Advisors first reported a position in MRNA in Q3 2020 and has held it in 19 quarters since. The position peaked at $3.11M in Q2 2025. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Snowden Capital Advisors held 5,196 shares of Moderna worth $364K as of Q2 2026.
  • Snowden Capital Advisors sold 7,526 Moderna shares in Q2 2026, an estimated $389K.
  • Moderna made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #990 holding.
  • Snowden Capital Advisors first reported a position in Moderna in Q3 2020 and has held it in 19 quarters since.
  • Snowden Capital Advisors's Moderna position peaked at $3.11M in Q2 2025.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.